Investment Rating - The investment rating for TCL Electronics is "Buy" [5]. Core Insights - The company has exceeded its equity incentive targets for 2025, with a strategic cooperation memorandum signed with Sony, accelerating its high-end and global strategies [2]. - The forecasted adjusted net profit for 2025 is between HKD 23.3 billion and HKD 25.7 billion, representing a year-on-year increase of 45% to 60% [9]. - The company maintains a leading position in the television market, with a projected global shipment of 30.41 million units in 2025, a 5.4% increase year-on-year [9]. Financial Summary - **Revenue Forecast (in thousand HKD)**: - 2023A: 78,986 - 2024A: 99,322 (+26%) - 2025E: 115,807 (+17%) - 2026E: 131,717 (+14%) - 2027E: 147,177 (+12%) [4] - **Net Profit Forecast (in million HKD)**: - 2023A: 744 - 2024A: 1,759 (+137%) - 2025E: 2,448 (+39%) - 2026E: 2,849 (+16%) - 2027E: 3,279 (+15%) [4] - **Valuation Ratios**: - PE: 2025E at 12.59, 2026E at 10.82, 2027E at 9.40 [4]. - PB: 2025E at 1.65, 2026E at 1.50, 2027E at 1.36 [4]. Strategic Developments - TCL Electronics has signed a strategic cooperation memorandum with Sony to establish a joint venture for home entertainment business, with TCL holding 51% and Sony 49% [9]. - The new company will operate under the "Sony" and "BRAVIA" brands, expected to start operations by April 2027 [9].

Investment Rating - The report assigns a "Buy" rating for the company, Minhua Holdings [3][57]. Core Insights - Minhua Holdings is the global leader in functional sofas, with a strong presence in both domestic and international markets. The company has successfully transitioned from a traditional export-oriented business to a model that balances export manufacturing with domestic brand sales [5][8]. - Recent financial performance shows a mixed trend, with a projected revenue decline of 8.2% in FY2025, but a slight recovery in net profit expected in FY2026 [5][15]. - The company is experiencing positive changes in its business operations, particularly in e-commerce sales, which have rebounded by 13.6% in FY26H1, reversing previous declines [28][39]. Financial Data and Valuation - Revenue projections for FY2024 to FY2028 are as follows: - FY2024: 18,411 million HKD - FY2025: 16,903 million HKD (down 8%) - FY2026: 16,392 million HKD (down 3%) - FY2027: 16,757 million HKD (up 2%) - FY2028: 17,424 million HKD (up 4%) [5][54]. - Net profit projections are: - FY2024: 2,302 million HKD - FY2025: 2,063 million HKD (down 10%) - FY2026: 2,067 million HKD (up 0.2%) - FY2027: 2,120 million HKD (up 2.5%) - FY2028: 2,208 million HKD (up 4.1%) [5][54]. - The company maintains a dividend payout ratio of around 50%, with a projected dividend yield of approximately 5.7% based on FY26 earnings [57]. Business Operations - The company has a balanced revenue structure with approximately 59% from domestic sales and 41% from international sales as of FY26H1 [6][17]. - The domestic sales model primarily focuses on the Zhihua brand, with a significant portion of revenue coming from sofas and mattresses [8][17]. - The company is pursuing strategic acquisitions, such as the planned acquisition of Gainline Recline Intermediate Corp, to enhance its business layout and operational synergies [39][41]. Profitability and Margin Analysis - The company has demonstrated resilience in profitability, with a net profit margin of 12.2% in FY2025, slightly below the previous year's 12.5% [43][54]. - Despite a decrease in average selling prices, the gross margin has improved, indicating strong cost control capabilities [43][54]. Investment Recommendations - The report suggests that Minhua Holdings, as a leader in the functional sofa market, is well-positioned for growth, particularly with its manufacturing advantages and recovery in online sales [57]. - The projected earnings for FY2026 to FY2028 indicate a gradual recovery in net profit, with expected growth rates of 0.2%, 2.5%, and 4.1% respectively [54][57].

Investment Rating - The report assigns a "Buy" rating to Shanghai Baoji Pharmaceutical with a target price of HK$ 111.30 [2][6]. Core Insights - Shanghai Baoji Pharmaceutical (02659.HK) is a biotechnology company focused on developing and providing recombinant biopharmaceuticals using synthetic biology technology, targeting complex diseases with limited treatment options [3][12]. - The company has established a product pipeline consisting of one approved drug and seven candidates in clinical stages, along with four preclinical assets [3][12]. - The company aims to address the pain points of traditional pharmaceuticals by producing biopharmaceuticals that can replace biochemical extraction products derived from animal organs, blood, or urine [5][12]. Business Overview - The company is currently focused on four strategic therapeutic areas: i) large-volume subcutaneous administration, ii) antibody-mediated autoimmune diseases, iii) assisted reproductive drugs, and iv) other recombinant bioproducts [3][12]. - The company has a clear commercialization model and timeline, expecting significant revenue contributions starting in 2026 from its core products KJ017 and SJ02, with KJ103 anticipated to contribute from 2027 [4][12]. Product Development - KJ017, a key product, is a highly glycosylated recombinant hyaluronidase designed for subcutaneous drug delivery, expected to receive NDA approval in Q1 2026 [8][22]. - KJ103, a recombinant IgG degrading enzyme, is the only product of its kind expected to be launched in China, targeting autoimmune diseases and transplant desensitization [8][31]. - SJ02, a long-acting recombinant FSH product, has been approved for marketing and is expected to significantly improve patient outcomes in assisted reproduction [39][40]. Financial Projections - The company forecasts revenues of HK$ 6.9 million in 2024, increasing to HK$ 530 million by 2027, with a gross margin projected to decline from 97.8% in 2024 to 82.7% in 2027 [6][10]. - The company is expected to incur net losses in the coming years, with projected losses of HK$ 160.4 million in 2024 and HK$ 30.8 million in 2027 [6][10]. Market Position - The company has a first-mover advantage in China for its core products, which have already been commercialized in some foreign markets, indicating a strong market demand [4][12]. - The company has established partnerships with other pharmaceutical and biotechnology firms to develop subcutaneous drug delivery solutions, enhancing its market presence [26][29].

Investment Rating - The report maintains a "Buy" rating for 德昌电机控股 (0179) [2][11] Core Views - The company has shown stable operations in the first three quarters of the 2025-2026 fiscal year, with future growth expected from its robotics and liquid cooling sectors [2][11] - Despite facing operational pressures in the Asia-Pacific region, the company is implementing vertical integration and increasing automation to enhance efficiency and reduce costs [11] - The company is well-positioned to leverage its deep technical expertise in motors to expand into humanoid robotics and liquid cooling solutions, which are anticipated to be significant growth areas [11] Financial Summary - Total revenue for the first three quarters of 2025-2026 was $2.73 billion, remaining flat year-on-year; automotive product revenue decreased by 2%, while industrial product revenue increased by 1% [11] - The company forecasts earnings per share (EPS) of $0.28 for 2025, $0.33 for 2026, and $0.36 for 2027, with a target price of HKD 52.80 based on a 24x PE ratio for the 2025 fiscal year [11][12] - Projected total revenues are $3.648 billion for 2025, $3.718 billion for 2026, $4.060 billion for 2027, and $4.436 billion for 2028, with net profits expected to be $263 million for 2025 and growing to $338 million by 2028 [10][12]

Investment Rating - The report does not specify a clear investment rating for the company [6] Core Insights - The company has demonstrated strong operational capabilities in IP management, with recent product innovations leading to increased sales potential for Q1 [1][2] - Recent stock buybacks, totaling over 300 million HKD, reflect the company's confidence in its long-term growth prospects and indicate that the stock price is at a relatively low level [1][3] - The company has successfully launched new product lines that have gained significant market traction, suggesting a robust ability to diversify its IP portfolio [2] Summary by Sections Product Performance - The Pucky Knock Knock series blind boxes have gained popularity, showcasing the company's innovative approach to IP [2] - The company has also launched successful series for the New Year and Valentine's Day, indicating strong consumer demand [2] Stock Buyback Activity - The company repurchased 1.4 million shares at an average price of 161 HKD and 500,000 shares at 173 HKD, demonstrating confidence in its stock valuation [3] - The stock buybacks are seen as a strategic move to bolster market confidence and counteract short-selling pressures [3] Market Outlook - The company has a strong presence in overseas markets, with approximately 200 stores globally, and continues to expand its footprint [4] - Future revenue projections indicate significant growth, with expected revenues of 373.98 billion RMB in 2025, reflecting a year-over-year growth of 186.8% [12] - The company's P/E ratios for 2025, 2026, and 2027 are projected to be 20.70, 15.25, and 12.26 respectively, suggesting that the current valuation is relatively low for a high-growth company [4][12]

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook for its stock performance [5]. Core Insights - The company is leading the ADC (Antibody-Drug Conjugate) iteration wave and is expected to achieve commercialization by 2026 [2][3]. - The company has received IND approval for its self-developed ADAM9 ADC drug DB-1317, allowing clinical trials in late-stage metastatic solid tumor patients [2]. - The HER2 ADC DB-1303 has reached its primary endpoint in a Phase III clinical trial for HER2-positive unresectable or metastatic breast cancer, accelerating its path to market [3]. - The company is expected to report significant clinical data in 2026, which could enhance its market position and revenue potential [9]. Financial Forecasts - Projected revenues for the company are as follows: 1,941 million RMB in 2024, 1,950 million RMB in 2025, 1,972 million RMB in 2026, and 2,100 million RMB in 2027, with growth rates of 8.7%, 0.5%, 1.1%, and 6.5% respectively [4]. - The net profit attributable to shareholders is forecasted to be -1,050 million RMB in 2024, -247 million RMB in 2025, -386 million RMB in 2026, and -341 million RMB in 2027, showing a significant improvement in 2025 with a growth rate of 76.5% [4]. - Earnings per share (EPS) are expected to be -11.75 RMB in 2024, -2.76 RMB in 2025, -4.31 RMB in 2026, and -3.82 RMB in 2027 [4].

SDICSI 2026 年 1 月 23 日 泡泡玛特(9992.HK) IP 持续出圈印证运营能力，回购体现公司信心 事件：近期，公司在品类上做了更多的创新尝试，PUCKY 敲敲系列盲盒的出 圈、星星人怦然星动系列销售火热、以及新年马力全开系列毛绒受热捧，都印 证了公司对 IP 的运营能力，预计给 Q1 的销售带来更多增量。此外，公司近 日连续进行回购，1 月 19 日和 1 月 21 日共斥资超 3 亿港元进行回购，这也 彰显了公司对于中长期发展的信心。此前股价已从顶部下跌近 4 成，近期估值 开始修复，但仍处于合理偏低水平，推荐持续关注。 报告摘要 新品持续热销，有望给 Q1 的销售带来更多增量。近期，泡泡玛特 Pucky 敲敲 系列盲盒出圈，该产品是泡泡玛特旗下 IP 之一 Pucky 毕奇的最新系列"Pucky 敲敲系列搪胶毛绒挂件"，售价 99 元/盒，有"机敏"、"快乐"、"缘分"、"幸 运"、"智慧"、"财富"和隐藏款"成功"。产品特性是带有声音互动功能，通过 拍打毕奇脑袋，可以发出清脆的类似敲击木鱼的声音，符合当下打工人热爱玄 学的精神状态。该系列也因其敲击玩法被称为"电子木鱼"而出圈，和此 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the market [7][8]. Core Insights - The company plans to raise HKD 2.338 billion through the issuance of convertible bonds with a low interest rate of 0.75%, aimed at optimizing its capital structure and enhancing liquidity [7]. - The company has a strong fleet with an average age of approximately 4.13 years, which contributes to its competitive edge and stable performance [7]. - The company has implemented a high dividend payout policy, including a special dividend plan, which reflects its commitment to shareholder returns [7]. Financial Data and Earnings Forecast - Total revenue projections for the company are as follows: - 2023: HKD 3,745 million - 2024: HKD 4,441 million - 2025E: HKD 4,286 million - 2026E: HKD 4,541 million - 2027E: HKD 4,821 million - The revenue growth rates are expected to be 12.37% in 2023 and 18.58% in 2024, with a decline of 3.49% in 2025 [6][8]. - Net profit forecasts are as follows: - 2023: HKD 1,902 million - 2024: HKD 2,106 million - 2025E: HKD 1,969 million - 2026E: HKD 2,179 million - 2027E: HKD 2,420 million - The net profit growth rates are projected at 12.86% in 2023 and 10.73% in 2024, with a decline of 6.51% in 2025 [6][8]. - The company’s earnings per share (EPS) are expected to be: - 2023: HKD 0.31 - 2024: HKD 0.34 - 2025E: HKD 0.32 - 2026E: HKD 0.35 - 2027E: HKD 0.39 [6][8]. Operational Highlights - The company has signed contracts for six new vessels in the first half of 2025, with a total contract value of USD 308 million, all of which are mid-to-high-end vessel types [7]. - The fleet consists of 143 vessels, with 121 in operation and 22 under construction, ensuring a diversified and competitive fleet structure [7]. - The company has successfully reduced its comprehensive financing cost to 3.1%, down 40 basis points from the beginning of the year, and has decreased its debt-to-asset ratio to 65.2% [7].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook for its stock performance [5]. Core Insights - The company is leading the ADC (Antibody-Drug Conjugate) innovation wave and is expected to achieve commercialization by 2026 [2][3]. - The company has received IND approval for its self-developed ADAM9 ADC drug DB-1317, allowing clinical trials in late-stage metastatic solid tumor patients [2]. - The HER2 ADC DB-1303 has reached its primary endpoint in a Phase III clinical trial for HER2-positive unresectable or metastatic breast cancer, accelerating its market approval process [3]. - The company is expected to report multiple clinical data readouts in 2026, which could significantly impact its growth trajectory [9]. Financial Forecasts - Projected revenues for 2024, 2025, 2026, and 2027 are 1,941 million, 1,950 million, 1,972 million, and 2,100 million RMB respectively, with growth rates of 8.7%, 0.5%, 1.1%, and 6.5% [4]. - The net profit attributable to shareholders is forecasted to be -1,050 million, -247 million, -386 million, and -341 million RMB for the same years, reflecting growth rates of -193.8%, 76.5%, -56.1%, and 11.5% [4]. - Earnings per share (EPS) are expected to be -11.75, -2.76, -4.31, and -3.82 RMB for 2024, 2025, 2026, and 2027 respectively [4]. Clinical Development and Pipeline - The company is advancing its ADC pipeline, including DB-1316, which aims to address existing ADC resistance issues and is set to enter clinical stages soon [9]. - Collaborations with BioNtech are expected to yield significant clinical data in 2026, enhancing the company's competitive position in the ADC market [9].

Investment Rating - The report maintains a "Buy" rating for the company [2] Core Insights - The company plans to raise HKD 2.338 billion through the issuance of convertible bonds with a low interest rate of 0.75%, which is below the current financing cost of 3.1%. This will help optimize the capital structure and enhance liquidity [7] - The company has a young and diverse fleet, with an average age of 4.13 years and a long average remaining lease term of 7.64 years, which contributes to stable performance [7] - The company has maintained a high dividend payout ratio and announced a special dividend of HKD 0.06 per share, indicating a strong commitment to shareholder returns [7] - The financial forecasts for 2025-2027 project net profits of HKD 20 billion, HKD 22 billion, and HKD 24 billion respectively, with corresponding P/E ratios of 7, 6, and 5 [7] Financial Data and Profit Forecast - Total revenue is projected to grow from HKD 3,745 million in 2023 to HKD 4,821 million in 2027, with a peak growth rate of 18.58% in 2024 [6] - Net profit is expected to increase from HKD 1,902 million in 2023 to HKD 2,420 million in 2027, with a growth rate of 12.86% in 2023 [6] - Earnings per share are forecasted to rise from HKD 0.31 in 2023 to HKD 0.39 in 2027 [6]